Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24059370.
- Also identified by DOI 10.2214/AJR.12.10240 and PMC identifier 3970265.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The purposes of this article are to review the current management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) based on the 2012 National Comprehensive Cancer Network guidelines and to describe the role of imaging in a multidisciplinary approach. The management of GEP-NETs has become complex, requiring a multidisciplinary approach. The World Health Organization classification of GEP-NETs has been revised; the U.S. Food and Drug Administration has approved molecular targeted agents (sunitinib, everolimus) for the treatment of pancreatic NETs; and the National Comprehensive Cancer Network clinical practice guidelines have been updated.
Medical subject headings
- Diagnostic Imaging
- Gastrointestinal Neoplasms
- Neuroendocrine Tumors
- Pancreatic Neoplasms